Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TTP 273 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LOGRA
  • Sponsors vTv Therapeutics LLC

Most Recent Events

  • 11 Jun 2019 Results of post hoc analysis of patients from the LOGRA study assessing efficacy of TTP273 on patients with stage 2 hypertension presented at the 79th Annual Scientific Sessions of the American Diabetes Association
  • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
  • 07 Sep 2017 According to a vTv Therapeutics media release, additional data will be presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top